Injectable “cocktail” hydrogel with dual‐stimuli‐responsive drug release, photothermal ablation, and drug‐antibody synergistic effect

Injectable “cocktail” hydrogel with dual‐stimuli‐responsive drug release, photothermal ablation, and drug‐antibody synergistic effect

Abstract The combination of the first‐line standard chemotherapeutic drug doxorubicin hydrochloride (DOX) and the molecular‐targeted drug Herceptin (HCT) has emerged as a promising strategy for human epidermal growth receptor 2 (HER‐2) overexpressing breast cancer treatment. However, insufficient dr...

Full description

Bibliographic Details
Main Authors: Li Zhao, Jiawen Xu, Yao Tong, Pengyu Gong, Fucheng Gao, Hui Li, Yanyan Jiang
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:SmartMat
Subjects:
dual‐stimuli‐responsive drug release
HER‐2 overexpressing breast cancer
injectable hydrogel
photothermal therapy
synergistic effect
Online Access:https://doi.org/10.1002/smm2.1148

Internet

https://doi.org/10.1002/smm2.1148

Similar Items